|  |
| --- |
| July 18, 2017Contact person Dr. Jürgen KrauterHead of Communications Nutrition & Care Phone +49 6181 59-6847Fax +49 6181 59-76847juergen.krauter@evonik.com |
| **Contact person specialized press****Michael Giffels**Head of CommunicationsAnimal NutritionPhone +49 6181 59 3763Fax + 49 6181 59 73763michael.giffels@evonik.com |

Evonik Nutrition & Care GmbH

Rellinghauser Straße 1-11

45128 Essen

Telefone +49 201 177-01

Fax +49 201 177-3475
Germany

www.evonik.com

Management Board

Dr. Reiner Beste, Chairman

Dr. Hans Josef Ritzert
Michael Gattermann
Markus Schäfer

Registered office Essen

Registered court

Essen local court

Commercial registry B 25784

HR no. FN 431387 v

Evonik starts marketing GutCare® PY1 in India and Bangladesh

Essen, Germany. Evonik will now offer the probiotic GutCare® PY1 in India and Bangladesh following the launches in the United States and China earlier this year.

GutCare® PY1 has a positive effect on the healthy balance of bacteria populations in the chicken gut which has been scientifically proven by numerous studies (*in vitro* and *in vivo*).

GutCare® PY1 contains the spores of the strain *Bacillus subtilis* DSM 32315.

“With our broad portfolio of amino acids and probiotics, we are able to fully support our customers on the road to sustainable animal nutrition targeting reduced use of antibiotics ", says Dr. Emmanuel Auer, Head of the Animal Nutrition business line at Evonik.

A healthy gut microbiome reduces the risk of inflammatory diseases that can lead to high costs in livestock production. Commonly caused by bacteria such as *Clostridium perfringens,* diseases are responsible for several billion US dollars of damage to the livestock industry annually.

Evonik had introduced GutCare® PY1 to the US-market in January and to the Chinese market in April this year. By the end of 2018, the company wants to be present in every Asian country with at least one probiotic.

For Evonik, GutCare® PY1 is the first probiotic from the company’s own development. Since the acquisition of the probiotic business of the Spanish company NOREL S.A. in 2016, Evonik offers two probiotics: Ecobiol® (*Bacillus amyloliquefaciens* CECT 5940) and Fecinor® (*Enterococcus faecium* CECT 4515).

In addition to product development, Evonik is also focusing on deciphering the mechanisms of the chicken gut. Our new simulation model will help to describe the interactions between nutrition, the immune system and the intestinal microbiotia *in vitro*. Based on these findings, a second step will be the development of new probiotics and feed additives that can help improve the chickens' sustainable growth.

Evonik has more than 60 years of experience in the production of essential amino acids for animal nutrition. Evonik supports customers in more than 100 countries to produce healthy and affordable food for the growing world population, while conserving natural resources and reducing the ecological footprint.

**Company information**

Evonik is one of the world leaders in specialty chemicals. The focus on more specialty businesses, customer-orientated innovative prowess and a trustful and performance-oriented corporate culture form the heart of Evonik’s corporate strategy. They are the lever for profitable growth and a sustained increase in the value of the company. Evonik benefits specifically from its customer proximity and leading market positions. Evonik is active in over 100 countries around the world with more than 35,000 employees. In fiscal 2016, the enterprise generated sales of around €12.7 billion and an operating profit (adjusted EBITDA) of about €2.165 billion.

**About Nutrition & Care**

The Nutrition & Care segment is led by Evonik Nutrition & Care GmbH and contributes to fulfilling basic human needs. That includes applications for everyday consumer goods as well as animal nutrition and health care. This segment employed about 7,500 employees, and generated sales of around
€4.3 billion in 2016.

**Disclaimer**

In so far as forecasts or expectations are expressed in this press release or where our statements concern the future, these forecasts, expectations or statements may involve known or unknown risks and uncertainties. Actual results or developments may vary, depending on changes in the operating environment. Neither Evonik Industries AG nor its group companies assume an obligation to update the forecasts, expectations or statements contained in this release.